On December 27, 2016, Endologix revealed that it is stopping shipments of its top selling product, AFX Endovascular AAA System, while it investigates a manufacturing issue with some sizes of the device. Following this news, Endologix stock has dropped as much as $1.69, or 23.5%, to $5.50 during intraday trading on December 27, 2016.
If you are aware of any facts relating to this investigation, or purchased Endologix shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/elgx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-endologix-inc-elgx-300383693.html
SOURCE Bronstein, Gewirtz & Grossman, LLC